Search scope:
排序: Display mode:
Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine
Hongmei Xu, Xuetao Cao
Frontiers of Medicine 2011, Volume 5, Issue 4, Pages 323-332 doi: 10.1007/s11684-011-0172-4
Emerging immunological strategies: recent advances and future directions
Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 805-828 doi: 10.1007/s11684-021-0886-x
Keywords: cancer immunotherapy bispecific antibodies small molecules chimeric antigen receptor T therapy cancervaccines
Developing effective tumor vaccines: basis, challenges and perspectives
XU Qingwen, CHEN Weifeng
Frontiers of Medicine 2007, Volume 1, Issue 1, Pages 11-19 doi: 10.1007/s11684-007-0003-9
Keywords: development conventional identification elucidation Successful immunotherapy
Coronavirus Variants—Will New mRNA Vaccines Meet the Challenge?
Jennifer Welsh
Engineering 2021, Volume 7, Issue 6, Pages 712-714 doi: 10.1016/j.eng.2021.04.005
Daniel Stadlbauer, Raffael Nachbagauer, Philip Meade, Florian Krammer
Frontiers of Medicine 2017, Volume 11, Issue 4, Pages 471-479 doi: 10.1007/s11684-017-0602-z
Keywords: universal influenza virus vaccine hemagglutinin stalk H7N9
Development Trends and Suggestions of Nucleic Acid Vaccines
Li Aihua, Yang Xuemei, Sun Yinan, Yuan Yakun, Yang Juntao
Strategic Study of CAE 2021, Volume 23, Issue 4, Pages 153-161 doi: 10.15302/J-SSCAE-2021.04.018
Keywords: ribonucleic acid (RNA) vaccine messenger RNA (mRNA) vaccine coronavirus disease 2019 (COVID-19) cancer
Cancer stem cell-immune cell crosstalk in the tumor microenvironment for liver cancer progression
Frontiers of Medicine 2024, Volume 18, Issue 3, Pages 430-445 doi: 10.1007/s11684-023-1049-z
Keywords: liver cancer cancer stem cell immune cell immunotherapy
A review of the safety and efficacy of current COVID-19 vaccines
Frontiers of Medicine 2022, Volume 16, Issue 1, Pages 39-55 doi: 10.1007/s11684-021-0893-y
Keywords: COVID-19 SARS-CoV-2 vaccine safety efficacy effectiveness immunogenicity
Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 942-942 doi: 10.1007/s11684-021-0876-z
Progress and challenges in RET-targeted cancer therapy
Frontiers of Medicine 2023, Volume 17, Issue 2, Pages 207-219 doi: 10.1007/s11684-023-0985-y
Keywords: pralsetinib selpercatinib RET-alteration lung cancer thyroid cancer tumor-agnostic therapy drug
Epithelial-to-mesenchymal transition in cancer: complexity and opportunities
Yun Zhang, Robert A. Weinberg
Frontiers of Medicine 2018, Volume 12, Issue 4, Pages 361-373 doi: 10.1007/s11684-018-0656-6
Keywords: epithelial-to-mesenchymal transition cancer metastasis cancer stem cell
Metformin for cancer prevention
Yonghua Yang
Frontiers of Medicine 2011, Volume 5, Issue 2, Pages 115-117 doi: 10.1007/s11684-011-0112-3
Orlistat induces ferroptosis-like cell death of lung cancer cells
Frontiers of Medicine 2021, Volume 15, Issue 6, Pages 922-932 doi: 10.1007/s11684-020-0804-7
Keywords: orlistat ferroptosis FAF2 lung cancer
Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance
Fung Zhao, Eric W.-F. Lam
Frontiers of Medicine 2012, Volume 6, Issue 4, Pages 376-380 doi: 10.1007/s11684-012-0228-0
The forkhead transcription factors FOXO and FOXM1 have pivotal roles in tumorigenesis and in mediating chemotherapy sensitivity and resistance. Recent research shows that the forkhead transcription factor FOXM1 is a direct transcriptional target repressed by the forkhead protein FOXO3a, a vital downstream effector of the PI3K-AKT-FOXO signaling pathway. Intriguingly, FOXM1 and FOXO3a also compete for binding to the same gene targets, which have a role in chemotherapeutic drug action and sensitivity. An understanding of the role and regulation of the FOXO-FOXM1 axis will impact directly on our knowledge of chemotherapeutic drug action and resistance in patients, and provide new insights into the design of novel therapeutic strategy and reliable biomarkers for prediction of drug sensitivity.
Keywords: FOXO3a FOXM1 transcription factor cancer drug resistance tumorigenesis
Low-dose CT for lung cancer screening: opportunities and challenges
Hongbing Shen
Frontiers of Medicine 2018, Volume 12, Issue 1, Pages 116-121 doi: 10.1007/s11684-017-0600-1
Lung cancer is among the most frequently diagnosed cancers worldwide and the leading cause of cancerScreening for lung cancer coupled with earlier intervention has long been studied as an approach to mortalityOn the basis of this finding, LDCT has been recommended for lung cancer screening in high-risk populationsThis paper summarizes and discusses the main observations and challenges of LDCT screening for lung cancerComplementary biomarkers and technical improvement are expected in the field of lung cancer screening
Keywords: lung cancer low-dose computerized tomography early detection opportunities challenges
Title Author Date Type Operation
Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine
Hongmei Xu, Xuetao Cao
Journal Article
Developing effective tumor vaccines: basis, challenges and perspectives
XU Qingwen, CHEN Weifeng
Journal Article
Universal influenza virus vaccines: what can we learn from the human immune response following exposure
Daniel Stadlbauer, Raffael Nachbagauer, Philip Meade, Florian Krammer
Journal Article
Development Trends and Suggestions of Nucleic Acid Vaccines
Li Aihua, Yang Xuemei, Sun Yinan, Yuan Yakun, Yang Juntao
Journal Article
Cancer stem cell-immune cell crosstalk in the tumor microenvironment for liver cancer progression
Journal Article
Midline2 is overexpressed and a prognostic indicator in human breast cancer and promotes breast cancer
Journal Article
Epithelial-to-mesenchymal transition in cancer: complexity and opportunities
Yun Zhang, Robert A. Weinberg
Journal Article
Role of the forkhead transcription factor FOXO-FOXM1 axis in cancer and drug resistance
Fung Zhao, Eric W.-F. Lam
Journal Article